CME Information
The Annual Meeting will provide continuing medical credits based on attendees’ participation in the activity. Attendees can claim credit by completing the evaluations for the sessions attended via a survey sent following the event. Completion of session and global evaluations is required, and evaluations may be submitted only once. Therefore, attendees should not begin evaluations until they have completed participation in the certified content for which they wish to claim credit.
Program Objectives
The 2024 Annual Meeting of the American Thyroid Association aims to:
- Provide a professional forum to discuss and apply the most recent knowledge pertaining to basic science and translational research appropriate for basic scientists and clinicians that care for issues related to thyroid.
- Differentiate the changes in guidelines and highlight best practices for adoption into clinical practice.
- Identify new and clinically relevant evidence-based management and treatment(s), using the most up-to-date clinical and scientific information.
Continuing Medical Education Credit Information
Accreditation
The American Thyroid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American Thyroid Association designates this live activity for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
General & Plenary Sessions are a total of 20 AMA PRA Category 1 Credits™
American Internal Medicine Board (ABIM) & Amercian Board of Otolaryngology – Head Neck and Surgery (ABOHNS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 26.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program; and Amercian Board of Otolaryngology – Head Neck and Surgery (ABOHNS) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.
American Board of Surgery Continuous Certification
Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
To submit credit on the learner’s behalf, ATA must have the learner’s date of birth on file.
Commercial Support
The American Thyroid Association acknowledges RGS Healthcare and Esaote for their in-kind support of this educational activity by providing ultrasound machines for the ultrasound workshop(s).
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American Thyroid Association ensures that anyone in a position to control the content of the educational activity (planners/speakers/authors/discussants/moderators) disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”) held in the last 24 months. Please note that first authors were required to collect and submit disclosure information on behalf of all other authors/contributors, if applicable.
The ACCME also requires that ATA manage any reported relevant financial relationships and eliminate the potential for bias during the educational activity. Any relevant financial relationships noted have been mitigated. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation. Any person not listed below did not have any relevant financial relationship(s).
Name of Individual | Individual’s Role(s) in Activity (e.g. Planner, Reviewer, Speaker, Author, Moderator, Panelist) |
Name of Ineligible Company(s) | Nature of Relevant Financial Relationship(s) |
Ali Alzahrani | Faculty | APSEN Newbridge Amgen |
Speaker (ended 02/2024); Advisor; Advisor |
Andrew J Bauer | Faculty | Egetis Pharmaceuticals; IBSA | Consultant |
Antonio C. Bianco | Faculty | Abbvie, Acella, Aligos, Synthonics | Consultant |
Benjamin Gigliotti | Moderator | Amgen (ended 7/24), Immunovant (ended 10/23) | Advisory Board |
Bhavana Konda | Faculty | Eisai; Merck; Xencor (ended) | Research Funding |
Bryan R Haugen | Faculty | Eisai (ended); Veracyte |
Consultant; Researcher |
Carla Moran | Faculty | Egetis | Advisor |
Cary N Mariash | Planner; Moderator | Horizon Therapeutics (Amgen) | Consultant |
Catherine A. Dinauer | Moderator | IBSA | Research Funding |
Chrysoula Dosiou | Faculty | Sling Immunovant Horizon (ended 09/23) Septerna (ended 06/24) Third Rock The Column Group (ended 05/23) |
Advisor Consultant Consultant Consultant Consultant Consultant |
Elizabeth Grubbs | Faculty | Eli Lilly; Exelixis | Research Funding |
Elizabeth N. Pearce | Faculty | Merck China | Speaker |
F. Thurston Drake | Faculty | Pfizer; Corcept Therapeutics; |
Speaker; Individual Stocks |
Ferdy van Geest | Faculty | Egetis Therapeutics AB | Consultant |
George J. Kahaly | Faculty | Immunovant | Researcher; Consultant |
Jennifer Hong Kuo | Moderator | Medtronic | Consultant |
Johnson Thomas | Moderator | AIBx (ended 7/24) | Ownership Interest |
Jonathon Russell | Faculty | Baxter Scientific (ended 9/24) | Consultant |
Josef Köhrle | Faculty | DiaSorin Deutschland GmbH (ended 2/23); IBSA Corporate (ended 1/24) | Speaker |
Julie Ann Sosa | Faculty; Moderator | Exelixis; Eli Lilly; Lilly Novo Nordisk; Astra Zeneca; Eli Lilly |
Research Funding; Consultant |
Julien Hadoux | Faculty | Lilly; Bayer; Eisai; Sanofi; IPSEN; Roche (ended 5/22) ITM (ended 3/22); HRA Pharma (ended 02/24) |
Advisor Speaker |
Kristien Boelaert, | Planner | Lilly, Serb(ended), Egetis Theraputics (ended) | Advisor |
Laura Ryan | Faculty | Amgen | Speaker |
Leonidas Duntas | Moderator | Merck (ended), Berline Chemie | Speaker |
Maisie Shindo | Faculty | Mender | Consultant |
Marcia S Brose | Moderator; Faculty | Bayer; Eusau; Ekkuosus; Exelixis; Aadi;Ipsen; Lilly | Consultant |
Marco Medici | Moderator | ACE Pharmaceuticals | Research Funding |
Maria Cabanillas | Faculty | Novartis; Merck; Exelixis (ended 09/23); Bayer (ended 9/22) |
Consultant research Funding Advisor Consultant |
Marina N. Nikiforova | Planner | Sonic Healthcare, USA University of Pittsburg |
Consultant IP ownership & royalties related to ThyroSeq |
Marius Stan | Faculty | Amgen, ArgenX, Avilar, Genentech, Immunovant, Lassen, Lundbeck, MingHiu Pharma, Septerna, Third Rock Vnetures, Tourmaline, Tshaka Inc, Viridian, Grofols (ended 5/24) | Consultant |
Mark Zafereo | Faculty | Eli Lilly; Merck; Exelixis |
Researcher |
Maya Lodish | Planner | Institut Biochimigque; Eli Lilly; Neurocrine; Recordati |
Researcher; Researcher; Consultant; Researcher |
Mayumi Endo | Moderator | Bayer (ended 12/23); Abbvie (ended 12/23) |
Consultant |
Melanie Goldfarb | Planner; Moderator | Starmed | Speaker |
Melinda Pierce | Faculty | Rhythm Pharmaceuticals (ended 10/23) | Advisor |
Mimi Hu | Faculty | Eli Lilly | Research Funding |
Nancy Reau | Faculty | Salix; VIR; Gilead; Arbutus; AbbVie (ended 7/24) |
Researcher, Consultant; Consultant; Researcher, Consultant; Consultant Researcher |
Nicole Massoll | Faculty | Interpace Diagnostics | Consultant |
Nikita Pozdeyev | Faculty | Veracyte | Research Funding |
Ralf Paschke | Faculty | Alberta Precision Laboratories | Royalties |
Robert Michael Tuttle | Faculty | Elesta (ended 8/24) | Researcher |
Robert Sargis | Faculty | CVS Health | Advisor |
Roopa Kanakatti-Shankar | Faculty | BioMarin | researcher |
Rossella Elisei | Faculty | Eisai; Ipsen; Lilly; Bayer; Roche | Consultant |
Rossella Elisei | Faculty | Eisai; Ipsen; Lilly; Bayer; Roche | Consultant |
Russell Smith | Faculty | Mendaera (ended 4/23) | Consultant |
Sara Ahmadi | Planner; Faculty | Veracyte | Research Funding |
Sean Wrenn | Faculty | StarMedUSA (ended 8/10/24) | Advisor |
Shoaib Ugradar | Faculty | Amgen | Consultant |
Sofie Bliddal | Moderator | Extempore | Speaker |
Steven I Sherman | Faculty | Novartis (Ended 8/31/2023); Bayer (Ended 3/19/2024; Eli Lilly (Ended 9/11/2024) Eli Lilly |
Consultant; Research Funding |
Steven Waguespack | Faculty | Bayer | Consultant |
Suzanne K Freitag | Faculty | Horizon, Viridian, Sling, Medtronic, Immunovant, Janssen, Kriya, WL Gore, Lassen, Poriferous, Third Rock/ASPEN | Consultant |
Thomas Scanlan | Moderator; Faculty | Autobahn Therapeutics | Consultant |
Tim Korevaar | Faculty | Berlin Chemie (ended 12/23); IBSA (ended 01/24); Merck (ended 05/24) |
Speaker |
Tim Korevaar | Faculty | Merk (ended 5/24); Berlin Chemie (ended 12/23); ISBA (ended 01/24) | Speaker |
Tracy Tylee | Moderator | AbbVie, Monod Bio | Advisor |
Victoria Banuchi | Faculty | Medtronic (ended 2/24) | Consultant |
Zoltan Antal | Planner; Faculty | Bayer | Consultant |
Francis Worden | Faculty | Eisai; Merck; Bayer; Exelexis |
Advisory Board/Consulting; Advisory Board; Advisory Board; Exelexis |
Elizabeth McAninch | Faculty | Acella Pharmaceuticals | Consultant |